ABBOTT PARK, Ill.,
Nov. 13, 2012
/PRNewswire/ -- Abbott (NYSE: ABT) announced today the results of its previously pending offers to purchase for cash any and all of its outstanding 4.35% Notes due
(the "2014 Notes"), 2.70% Notes due
(the "2015 Notes"), 5.875% Notes due
(the "2016 Notes") and 5.60% Notes due
(the "2017 Notes" and, collectively with the 2014 Notes, the 2015 Notes and the 2016 Notes, the "Any and All Notes," and such offers, the "Any and All Offers"). As of the expiration of the Any and All Offers at
Nov. 9, 2012
(such date and time, the "Any and All Expiration Date"),
principal amount of the 2014 Notes,
principal amount of the 2015 Notes,
principal amount of the 2016 Notes and
principal amount of the 2017 Notes have been validly tendered and not validly withdrawn in the Any and All Offers.
Subject to the terms and conditions of the Any and All Offers, Abbott expects that later today it will accept for purchase and pay for all Any and All Notes validly tendered and not validly withdrawn. On
Nov. 9, 2012
, Abbott called for redemption all of the Any and All Notes that will remain outstanding following the completion of the Any and All Offers, in accordance with the terms of the Indenture.
Abbott's previously announced offers to purchase for cash up to an aggregate principal amount of
of its 5.125% Notes due
(the "2019 Notes"),
of its 4.125% Notes due
(the "2020 Notes"),
of its 6.15% Notes due
(the "2037 Notes"),
of its 6.00% Notes due
(the "2039 Notes") and
of its 5.300% Notes due
(the "2040 Notes" and, collectively with the 2019 Notes, the 2020 Notes, the 2037 Notes and the 2039 Notes, the "Partial Offer Notes," and such offers, the "Partial Offers") remain pending and are scheduled to expire at
Nov. 26, 2012
. The Partial Offer Notes, collectively with the Any and All Notes, are referred to as "Notes." The Any and All Offers and the Partial Offers are collectively referred to as the "Tender Offers."
The Tender Offers are being made pursuant to an Offer to Purchase, dated
Oct. 26, 2012
(the "Offer to Purchase") and related Letter of Transmittal, dated
Oct. 26, 2012
(the "Letter of Transmittal"), which set forth a description of the terms of the Tender Offers. This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Tender Offers are being made solely pursuant to terms and conditions set forth in the Offer to Purchase and the Letter of Transmittal.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacturing and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.